This Is MS Multiple Sclerosis Community: Knowledge & Support

Biogen Idec and Elan Corporation announced findings from several studies of Tysabri(R) (natalizumab) evaluating its long-term safety and efficacy in the treatment of multiple sclerosis (MS) across the course of disease and impact on MS-related symptoms such as fatigue. These data, as well as data relating to the companies' risk stratification algorithm as a way to help enable individual benefit risk assessment for patients with MS, were accepted for presentation at the 64th Annual Meeting of the American Academy of Neurology (AAN).

"We continue to build on the extensive data we have for Tysabri and are committed to studying its long-term use and potential effect on symptoms like fatigue, which MS patients struggle with every day," said Douglas E. Williams, Ph.D., executive vice president of Research and Development at Biogen Idec. "Our research is aimed at discovering additional ways Tysabri can help physicians and patients best manage the symptoms of MS and make informed and personalized treatment choices."... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1768

_________________
The Multiple Sclerosis Resource Centre

Squiffy's House of Fun - Laughter for Multiple Sclerosis